Navigation Links
MiMedx Announces Record First Quarter 2013 Results
Date:5/1/2013

l in the remaining Medicare intermediaries' reimbursement decisions relative to our allografts."

During the quarter, the Company was granted four U.S. patents for its amnion technology. "We have been extremely diligent in the protection of our intellectual property. In fact, in the most recent quarter, we filed 11 non-provisional applications for our amnion technology," said Taylor.

MiMedx expects to begin its relocation to a new facility during the second quarter. "The new 80,000 square feet facility will house both our corporate headquarters functions and our operations. This is a major undertaking that will involve a number of individuals focused on a smooth transition. We are putting contingency plans in place to prevent any disruptions that can be associated with such a significant undertaking," added Taylor.

Balance Sheet Total assets increased by $2.7 million to $37.9 million and total liabilities decreased from $15.2 million to $6.3 million during the quarter. Cash on hand as of March 31, 2013, was $5.7 million, a decrease of $1.0 million, as compared to $6.7 million, as of December 31, 2012. Accounts receivable increased to $9.8 million from $7.7 million as of year-end due to the ramp up in commercial wound care sales in the latter half of the first quarter. Inventory increased by $900,000 as planned in anticipation of increased demand in commercial wound care sales in subsequent quarters. The decline in total liabilities was primarily the result of conversion of the senior secured promissory note and the final payout of the earnout related to the acquisition of Surgical Biologics. Stockholders' equity increased by $11.6 million to $31.6 million as of the end of the quarter.

GAAP EarningsThe Company recorded a Net Loss of $1.6 million, or $0.02 per diluted common share, for the quarter ended March 31, 2013, as compared to the Net Loss of $1.1 million, or $0.01 per diluted common share, recorded for the quarter ended March 31,
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
3. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
4. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
5. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
6. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
7. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
10. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... its Board of Directors.  Mr. Voyticky is currently President ... an oil and gas exploration company, and has more ... merger and acquisition consulting. The Genesis Biopharma Board now ...
... WOODLANDS, Texas, July 18, 2011 One of the ... to achieve Meaningful Use requirements in the coming years. ... learning more about Meaningful Use requirements and how these ... a free webinar at 1 p.m. EDT (10 a.m. ...
... 90% , Reduction in HIV ... SEEK, a privately owned biopharmaceutical company specializing,in ... of its HIV-v vaccine which demonstrates a one,log (approx ... placebo group, after just a single vaccine,injection. Gregory Stoloff, ...
Cached Biology Technology:Genesis Biopharma Names David Voyticky to Board of Directors 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:8/19/2014)... , August 19, 2014 Smart ... Digital Wallet Choices as latest developments, ad campaigns and ... (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:8/19/2014)... protect their young have bigger brains than counterparts that ... British Columbia study. , Stickleback fish are well known ... male of the species, rather than the female, cares ... females and researchers wanted to find out if the ... caregivers. , In the study, published recently in ...
(Date:8/18/2014)... major Arizona watershed may lose access to important segments ... is reduced by the effects of climate warming, new ... in the Verde River Basin, are already threatened or ... resources throughout the river and its tributary streams. The ... (Gila robusta) and Sonora sucker (Catostomus insignis). , A ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... at Johns Hopkins have discovered how to block a molecular ... oxygen during a stroke. The Hopkins study, conducted on mice, ... protein on the surface of nerve cells called the EP1 ... as ONO-8713, turns it off. , The finding ...
... garden compost to forest greenery, the mold Aspergillus fumigatus ... its impact. The most common mold causing infection, A. ... among people with weakened immune systems. , Now, in ... scientists at The Institute for Genomic Research (TIGR) and their ...
... Chinese men are selectively switching from traditional Chinese ... but sticking with tradition for ailments such as ... published in Environmental Conservation. , The finding supports ... at the advent of Viagra's commercial release in ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Breaking the mold: Research teams sequence three fungus genomes 2Viagra's hidden help for wildlife 2
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
Biology Products: